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امزلابلا تايوتسم ،يويلحا رفاوتلا ىلع )سيلدأ اثاك( تاقلا مادختسا يرثأت 
ايرلاملل داضلما ينكورولكلا طاشنو
س�ناس� لكيام ،يروبلحا مهلم ،ىس�يع ةزياف
abstract: Objectives: This study aimed to evaluate the effect of khat (Catha edulis) on chloroquine (CQ) 
bioavailability in healthy Yemeni adults and its effect on CQ plasma levels and parasite clearance among malaria 
patients. Methods: This study took place between January and April 2007 in Bajil and Sana’a, Yemen. Two CQ doses 
(600 mg each) were given to 15 healthy males on separate occasions; the first dose was followed by a khat-chewing 
session (phase one) while controls abstained from khat-chewing for the second (phase two). Additionally, 103 
patients with Plasmodium falciparum-induced malaria, including both regular khat chewers (n = 57) and non-khat 
chewers (n = 46), were treated with CQ (25 mg/kg) over three days. Pharmacokinetic parameters were analysed 
among both controls and malaria patients. Parasite clearance was also investigated for the latter group. Results: 
The mean area under the concentration-time curve (AUC) was 2,108.9 versus 2,797.4 ng/hour/mL, mean peak 
plasma concentration (Cmax) was 415.6 versus 508.7 ng/mL and mean time to reach Cmax was 3.8 versus 3.6 hours 
for controls in phase one versus phase two, respectively; both AUC and Cmax levels were significantly reduced by 
khat-chewing (P <0.050). For khat- versus non-khat-chewing malaria patients, mean plasma CQ concentrations 
were 266.4 ng/mL versus 427.5 ng/mL (P <0.001). Furthermore, CQ was effective in 71.7% and 75.4% of non-khat 
and khat-chewing malaria patients, respectively (P = 0.823). Conclusion: Khat-chewing was found to significantly 
reduce plasma CQ levels among healthy volunteers and malaria patients. While receiving CQ treatment, patients 
should be advised not to chew khat.
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 ينينميلا ءاحس�ألا ينغلابلا في )CQ( ينكورولكلا راقعل يجولويبلا رفاوتلا ىلع تاقلا يرثأات مييقت لىإا ةس�اردلا هذه تفده :فادهأا :ص�خللما
 ةترفلا في ةس�اردلا هذه تيرجأا :ةيجهنم .ايرلالما ىس�رم ينب تايليفطلا ةلازإا ىلع هتردقو ينكورولكلل امزلابلا تايوتس�م ىلع اهيرثأاتو
 في ءاحس�ألا روكذلل 15  لىإا  امهنم لكل غلم 600  ينكورولكلا نم ينتعرج تيطعأا  .نميلا ءاعنس�و لجاب في 2007  ليربأاو رياني ينب ام
 تاقلا غس�م نع ةطباس�لا ةعومجلما تعنتما امنيب ،)لىوألا ةلحرلما( تاقلا غس�لم ةس�لج لىوألا ةعرلجا تبقعأاو ةلس�فنم تابس�انم ةدع
 نوغس�يم نيذلا ىس�رلما تلمس�و يلجنلما مويدومزلابلا اهببس�ي يتلا ايرلالماب اس�يرم 103 جلاع تم ،كلذ لىإا ةفاس�إلاب .)ةيناثلا ةلحرلما(
 دقو .مايأا ةثلاث ىدم ىلع ينكورولكلا راقع نم غلك/غلم 25 ةعرج ةطس�اوب ،)46 = ن( تاقلا نوغس�يمل نيذلاو )57 = ن( ماظتناب تاقلا
 :جئاتن .ةيناثلا ةعومجملل اس�يأا تايليفطلا ةلازإا نم ققحتلا تمو .ايرلالما ىس�رم و ةطباس�لا ةعومجلما نم لك في ءاودلا ةيكرح ليلتح تم
 امزلابلا زيكرت ةورذ طس�وتم ناك امنيب ،لم/ةعاس�/مارغونان 2,797.4 لباقم 2,108.9 وه ينمزلا زيكترلا ىنحنم تتح ةقطنلما طس�وتم ناك
 ةلحرلما في ةطباس�لا ةعومجملل ةعاس� 3.6 لباقم 3.8 ناك Cmax لىإا لوس�ولا تقو طس�وتمو لم/مارغونان 508.7 لباقم )Cmax( 415.6(
 عم ايئاس�حا ظوحلم لكس�ب Cmax لا و ينمزلا زيكترلا ىنحنم تتح ةقطنلما طس�وتم س�فخنا .لياوتلا ىلع ،ةيناثلا ةلحرلما لباقم لىوألا
 لباقم تاقلا نوغس�يمل نيذلا ىس�رلما لم/مارغونان 427.5 يه ينكورولكلل امزلابلا تازيكرت طس�وتم تناك .)P >0.050( تاقلا غس�م
 ىس�رلما في 71.7%في لاعف ينكورولكلا راقع ناك ،كلذ ىلع ةولاعو .)P >0.001( تاقلا يغس�ام ىس�رلما في في لم/مارغونان 266.4
 يربك يرثات تاقلا غس�لم :ةتمالخا .)P = 0.823( لياوتلا ىلع تاقلا يغس�ام ايرلالما ىس�رم نم 75.4% و لباقم تاقلا نوغس�يمل نيذلا
 تاقلا غس�م نع فقوتلاب ىس�رلما ءلؤوه حس�ن بجي كلذل .ايرلالما ىس�رمو ءاحس�ألا روكذلا في ينكورولكلا راقع زيكرت س�افحنا ىلع
.جلاعلا يقلت ءانثا
.نميلا ؛ينكورولكلا ؛يلجنلما مويدومزلابلا ؛ايرلالما ؛س�يلدأا اثاك ؛تاق :ةيحاتفم تاملك
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Advances in Knowledge
- This is the first study to reveal that the use of khat (Catha edulis) significantly reduces plasma chloroquine (CQ) levels among malaria 
patients receiving CQ treatment.
- The results of this study may be used as a reference for future research on possible interactions between khat and other drugs.
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Application to Patient Care
- Chewing khat was found to significantly reduce plasma CQ levels among malaria patients. Health workers and medication 
manufacturers should be educated regarding the potential risk of CQ and khat co-administration and patients should be advised to 
abstain from khat-chewing whilst undergoing CQ treatment.
- The rate of CQ resistance noted in this study was above the threshold recommended by the World Health Organization. This indicates 
that current antimalarial drug practices in Yemen need to be modified.
Certain dietary substances can affect the absorption of medications, including antimalarial drugs.1–6 Drug-food, drug-drug 
and drug-herb interactions are factors that can alter the 
pharmacokinetic activity of a drug; these interactions 
can occur during absorption, distribution, metabolism 
or excretion.7 Catha edulis of the Celastraceae family, 
also known as khat, is a plant widely cultivated in 
East Africa (e.g. Kenya and Ethiopia) and the Arabian 
Peninsula.8 The main active substances in fresh khat 
leaves are alkaloids with amphetamine-like properties 
which have euphoric and stimulatory effects.9 
In Yemen, khat-chewing is a widespread habit; 
approximately 80–85% of male and 50–60% of female 
adults in Northern Yemen chew khat at least once 
a week.8 The concurrent use of khat with standard 
medications is anecdotally purported to be common 
practice in Yemen. Attef et al. found that khat-chewing 
among healthy Yemeni adults significantly reduced 
the bioavailability of the antibiotics ampicillin and 
amoxicillin.10 Another study observed a significant 
reduction in the pharmacokinetic parameters of 
tetracycline-hydrochloride among healthy Yemeni 
adults after a khat-chewing trial.11
Malaria is a serious health concern in Yemen, 
with an estimated 800,000–900,000 malaria cases 
occurring each year.12 The disease is responsible for 
significant child morbidity and mortality; 1% of deaths 
among Yemeni children under five years of age are 
attributed to malaria.13 Recently, a study revealed 
that repeated dosing with extracts of khat reduced 
parasite loads among Swiss albino mice with malaria 
infections.14 However, Ketema et al. found that khat 
exhibited only mild antimalarial activity among khat 
chewers in Ethiopia.15 Chloroquine (CQ) is one of 
the most common antimalarial drugs prescribed 
by Yemeni physicians.16 Consequently, determining 
whether khat-chewing has an effect on CQ is of great 
importance. This study was undertaken to investigate 
the effect of khat use on CQ bioavailability in both 
healthy volunteers and malaria patients. In addition, 
the effect of khat use on parasitaemia and parasite 
clearance among the latter group was also examined.
Methods
This study was carried out between January and April 
2007 in Bajil and Sana’a, Yemen. Healthy volunteers 
and malaria patients made up the control and patient 
groups, respectively. A total of 15 healthy males >18 
years old and between 45‒64 kg were recruited from 
Sana’a, the capital city of Yemen, which is free of 
malaria.16 The healthy volunteers were selected from a 
group of respondents to an advertisement requesting 
participants for an unpaid pharmacological study. 
Volunteers with blood film examinations negative 
for malaria parasites, normal standard laboratory 
test results (including haemoglobin [Hb] levels, a 
complete blood count and kidney and liver function 
tests) and who were otherwise healthy with no history 
of clinical illness were included in the control group. 
Individuals with a history of taking antimalarial or 
prophylactic drugs over the preceding 12 months 
and those who were unwilling to abstain from khat-
chewing for a period of 72 hours were excluded. 
For the patient group, all patients >18 years old who 
presented to the National Malaria Control Centre in 
Bajil, Al-Hudaydah Governorate, West Yemen, with 
microscopy-confirmed Plasmodium falciparum-
induced malaria were recruited (n = 103). This area 
was identified as a meso- to hyperendemic area for 
malaria between January−April 2007.17 All patients 
had a P. falciparum-positive thick or thin blood smear 
and were seeking treatment for uncomplicated malaria 
with no signs of severe malaria, such as an inability 
to drink/eat or sit/stand upright, repeated vomiting, 
convulsions, lethargy or unconsciousness and Hb 
levels of <7 g/dL. The presence of a documented fever 
was not required for enrolment in the study.
The control group underwent two phases of CQ 
administration. In the first phase, a single dose of 
CQ (600 mg) was administered orally to the healthy 
volunteers immediately before a khat-chewing session 
which involved chewing ~250 g of fresh khat leaves 
for 4–5 hours. The second phase occurred four weeks 
later; participants received a second single dose of 
CQ (600 mg) after having been instructed to abstain 
from khat-chewing for the preceding 48 hours. In 
addition, they were also requested to refrain from 
khat-chewing for 24 hours on the day of dosing. All 
of the participants clearly understood the purpose 
of the study and had agreed to abstain from khat-
chewing for the required period of time. The principle 
investigator contacted all of the volunteers two days 
before their second CQ dose to reiterate the necessity 
of abstaining from khat-chewing. For both stages, 3 
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mL of venous blood was collected from the subjects 
before and during CQ administration, at 0.5, one, 
two, three, four, six, eight, 12 and 24 hours after each 
dose. Samples were transferred to heparinised tubes 
and the plasma was separated and stored at -75 °C 
until analysis. Several studies have shown that CQ 
levels are negligible four weeks after a single dose.18,19 
Furthermore, active components of khat, cathine and 
cathinone are reportedly undetectable 24 hours after 
chewing.20 As a result, residual levels of either the first 
dose of CQ or khat would not interact with the CQ 
dose administered during the second phase. 
Malaria patients were divided into regular khat 
chewers and non-khat chewers. Patients were 
considered khat chewers if they reported chewing 
khat more than three days a week. For khat-chewing 
patients, the amount and type of khat used and 
the timing of the khat-chewing sessions was not 
controlled by the researchers. On average, khat 
chewers reported using 230–350 g of fresh khat leaves 
for 4–5 hours per session. All of the malaria patients 
received oral CQ tablets administered over three 
days, at 10 mg/kg for the first two days and 5 mg/kg 
on day three, resulting in a total dose of 25 mg/kg. 
The full dose was readministered if the patient vomited 
within 30 minutes of the initial dose. A total of 3 mL 
of venous blood was drawn and transferred into 
heparinised tubes the day before CQ dosing (day zero) 
and during CQ treatment (days 1–3), 24 hours after 
the dose had been administered. Body temperature 
was recorded during treatment as a marker of illness/
clinical cure. In addition, parasitaemia was routinely 
assessed on each visit by counting the number of 
asexual parasites against at least 200 white blood cells 
(WBCs) in thick blood films, assuming a normal WBC 
count of 8,000/µL.21 Patients were followed-up for 
three days after the first dose of CQ. 
A validated high-performance liquid chromato-
graphy (HPLC) method was used to determine plasma 
CQ concentrations in the blood samples of both healthy 
controls and malaria patients using the LC-2010HT 
system (Shimadzu Corp., Kyoto, Japan) with an auto 
sampler.22 Ultraviolet detection of eluted peaks was 
performed at 340 nm. Chromatographic separation 
was carried out using the reversed-phase 150 mm x 
4.6 mm HypersilTM BDS C18 HPLC Columns (Thermo 
Fisher Scientific Inc., Waltham, Massachusetts, USA) 
with a 5 µm particle size. The mobile phase contained 
a mixture of water and acetonitrile (ratio: 85:15%) 
as well as 1% triethylamine adjusted to a pH of 2.8 
with concentrated phosphoric acid and a flow rate 
of 1 mL/minute. The pharmacokinetic parameters of 
CQ were determined by measuring the area under 
the concentration-time curve (AUC) from time zero 
(before the CQ dosing) to 24 hours after CQ dosing, 
maximal plasma drug concentration (Cmax) and time 
taken to reach maximum plasma concentration 
(Tmax). These parameters were calculated using the 
compartmental/trapezoidal method with Kinetica 
Software for PK/PD Data Analysis, Simulation and 
Reporting, Version 4.4 (Thermo Fisher Scientific Inc.). 
Values were reported as means ± standard deviation.
Among the malaria patients, parasitological and 
clinical responses to CQ treatment were classified 
according to different treatment protocols devised by 
the World Health Organization (WHO) and Osorio 
et al.23–25 In terms of parasitological response, the 1973 
WHO protocol was utilised—patients were deemed 
to exhibit sensitivity (S)/resistance level I (RI) if the 
P. falciparum parasites had cleared by day two of 
CQ treatment; RII if there was incomplete clearance 
of parasites by day two; and RIII if parasite density 
on day two was ≥25% that of the parasite density 
observed on day zero.23 Clinical responses to CQ 
were classified according to definitions used within 
the 1996 WHO treatment protocols and methods 
of Osorio et al.24,25 Early treatment failure (ETF) was 
defined as (1) the development of any danger signs, 
such as fever and vomiting, severe malaria or parasite 
positivity on days 1–3 of CQ administration; (2) higher 
parasitaemia levels on day two than day zero; or (3) 
parasite density on day three ≥25% that of day zero.24 
Treatment success (TS) was classified as negative 
parasitaemia on day three.24 Late treatment failure 
(LTF) was defined as the development of any danger 
signs, severe malaria, parasitaemia or fever after day 
three or an unscheduled return to seek medical help 
because of clinical deterioration or parasitaemia on 
any scheduled follow-up day on or after day seven.25 In 
this study, follow-up after three days was not possible. 
Patients who failed to respond to CQ treatment 
were prescribed sulfadoxine/pyrimethamine. During 
follow-up, patients received a single dose of primaquine 
(0.75 mg/kg) at the end of the follow-up period if they 
were found to have gametocytaemia. 
The t-test for paired values was used to compare 
pharmacokinetic parameters of CQ obtained after the 
two phases of the control group trial and to compare 
results between khat-chewing and non-khat-chewing 
malaria patients. Geometric means were used to 
summarise parasite densities for malaria patients. 
Parasite clearance and the association with khat use 
were analysed with a two-sided Fisher’s exact test. A 
P value of <0.050 was used as the level of significance.
This study was approved by the institutional review 
boards of the Faculty of Medicine & Health Sciences 
at Sana’a University and the National Malaria Control 
Programme (NMCP) in Sana’a. In addition, ethical 
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permission was granted by the Liverpool School of 
Tropical Medicine in Liverpool, UK. Informed consent 
was obtained from all individuals before participation 
in the study.
Results
The control group ranged in age from 20–30 years 
old and had a mean Hb level of 16.2 g/dL and mean 
body weight of 62.86 kg. In phase two versus phase 
one, there was a significant reduction in mean Cmax 
and AUC among the healthy controls (415.6 versus 
508.7 ng/mL and 2,108.9 versus 2,797.4 ng/hour/mL; 
P <0.001 and 0.002, respectively) [Figure 1]. However, 
no significant difference was seen in mean Tmax
(3.8 versus 3.6 hours; P = 0.81) [Table 1]. The malaria 
patient group ranged in age from 20–45 years old and 
there were 57 khat chewers and 46 non-khat chewers. 
Of the khat and non-khat chewers, 25 (43.9%) and 27 
(58.7%) were female and 32 (56.1%) and 19 (41.3%) 
were male, respectively. All patients had a temperature 
of >37 °C prior to treatment and had normal axillary 
temperatures by day three of CQ treatment. Plasma 
CQ levels among khat- and non-khat-chewing malaria 
patients according to day of treatment are presented in 
Table 2. Plasma CQ levels were significantly reduced 
among khat-chewing malaria patients compared to 
their non-khat-chewing counterparts (266.4 ± 164.3 
and 427.5 ± 125.6, respectively; P <0.001). 
Before CQ treatment, parasite density among 
the malaria patients ranged from 48–256,800 to 
32–111,760/µL for non-khat and khat chewers, 
respectively. No danger signs or severe malaria 
symptoms were recorded for any of the patients. 
Geometric mean parasitaemia before treatment was 
1,494/µL (95% confidence interval [CI]: 771–3,837/µL) 
and 1,861/µL (95% CI: 902–2,890/µL) for khat and 
non-khat chewers, respectively. On day three of CQ 
treatment, the geometric mean parasite density was 
3/µL (95% CI: 1.7–5.2/µL) and 4/µL (95% CI: 
1.9–7.9/µL) for khat and non-khat chewers, 
respectively. There was no significant difference 
in mean parasite density (P = 0.652 and 0.563, 
respectively) and axillary temperature (P = 0.140 
and 0.145, respectively) between khat and non-khat 
chewers before treatment and on day three [Table 3].
Among the malaria patients, parasitaemia had 
cleared completely (S/RI) by day two of CQ treatment 
for 61 patients (59.2%) while the remaining 42 patients 
(40.8%) showed resistance at either the RII or RIII 
levels. Among non-khat chewers, 27 (58.7%) patients 
were completely clear of parasites by day two, while 19 
(41.3%) showed parasitological resistance. However, 
CQ was effective for 34 khat chewers (59.6%) while 23 
non-khat chewers (40.4%) were not clear of parasites by 
day two. There was no significant difference in overall 
resistance (RII and RIII) between the two groups 
(P = 0.394). Among the patient group, 76 (73.8%) had 
Table 1: Effect of khat-chewing on the pharmacokinetic 
parameters of chloroquine* among healthy adult males 
in Yemen (N = 15)
Parameter Mean ± SD P 
value
After 48-hour 
khat-chewing 
abstinence 
period
After khat-
chewing 
session†
AUC in ng/
hour/mL
2,797.4 ± 845.9 2,108.9 ± 682.3 0.002
Cmax in ng/mL 508.7 ± 106.4 415.6 ± 103.1 <0.001
Tmax in hours 3.6 ± 0.5 3.8 ± 0.4 0.810
SD = standard deviation; AUC = area under the time-concentration 
curve; Cmax = peak plasma concentration; Tmax = time to reach peak 
concentration.
*Single dose of 600 mg.  †Approximately 250 g of fresh khat leaves for 
4–5 hours.
Table 2: Effect of khat-chewing on chloroquine 
plasma levels among malaria patients in Yemen after 
chloroquine treatment* (N = 103)
Day of 
treatment
Mean plasma level ± SD P value
Non-khat 
chewers 
(n = 46)
Khat chewers 
(n = 57)
Day one 216.5 ± 94.8 145.4 ± 73.8 <0.001
Day two 313.3 ± 123.4 202.7 ± 130.1 <0.001
Day three 427.5 ± 125.6 266.4 ± 164.3 <0.001
SD = standard deviation.
*Total dose of 25 mg/kg over three days.
 
Figure 1: Mean plasma concentration-time curves of 
chloroquine* after a khat-chewing session† and after 
a 48-hour khat-chewing abstinence period among 
healthy adult males in Yemen (N = 15).
CQ = chloroquine; VCQK = after a khat-chewing session; VCQ = after 
a 48-hour khat-chewing abstinence period.
*Single dose of 600 mg.  †Approximately 250 g of fresh khat leaves 
for 4–5 hours.
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TS/LTF while 27 (26.2%) had ETF. Overall, rates of TS/
LTF were 71.7% and 75.4% among non-khat- and khat-
chewing malaria patients, respectively (P = 0.823). 
There was no significant difference between khat
and non-khat chewers in terms of ETF (P = 0.823) 
[Table 4].
Discussion
The co-administration of CQ and khat was found 
to significantly affect the pharmacokinetics of CQ 
among both healthy controls and malaria patients in 
Yemen. This was comparable to reported reductions 
in the pharmacokinetic activity of tetracycline 
hydrochloride and the low bioavailability of ampicillin 
and amoxicillin when co-administered with khat.10,11 
A possible drug-plant CQ-khat interaction exists, as 
indicated by the significantly reduced CQ AUC and 
Cmax values observed with khat use in the present 
study. The mechanisms underlying this interaction 
are unknown; however, one possible mechanism may 
relate to the interaction of the drug with some of khat’s 
components—tannic acid, cathinone and cathine—
which are known to cause the formation of insoluble 
complexes and non-absorbable compounds.10,11 In 
particular, it has been hypothesised that tannins 
in khat may interfere with absorption processes 
in the gastrointestinal tract.10 Changes in gastric 
acidity and motility or the delay of gastric emptying 
may slow absorption of CQ, as these changes will 
prolong the duration of time that the drug remains 
in the stomach.3,26 Finally, increased diuresis is often 
reported among khat chewers, possibly due to fluid 
intake during khat-chewing sessions;26 this may lead 
to increased urinary excretion of CQ. Other possible 
mechanisms of pharmacokinetic interactions between 
khat and CQ require further investigation.
In the current study, CQ plasma levels were 
significantly reduced among khat-chewing malaria 
patients in comparison to non-khat-chewing patients. 
This may be associated with the general health of this 
patient group with regards to malnutrition, anaemia 
and parasitic infestation; Tulpule et al. found faster 
clearance of CQ in undernourished subjects.5 In 
general, khat-chewing-induced symptoms include 
loss of appetite and malnutrition.9 This may also affect 
digestion or absorption of CQ. In addition, differences 
in plasma CQ levels between healthy controls and 
malaria patients could be related to the age differences 
between the two groups. Edwards et al. reported that 
CQ blood concentrations and AUC were significantly 
higher in malaria patients receiving oral CQ treatment 
than in healthy subjects, suggesting that malaria 
induces absorption changes and increases systemic 
exposure to CQ.27 In the current study, reduction in 
the plasma CQ levels among khat-chewing malaria 
patients could be related to impaired gastrointestinal 
absorption due to the effect of khat on CQ absorption. 
In the current study, the rate of CQ resistance 
among the malaria patients was above the acceptable 
level of resistance determined by the WHO.24 Several 
studies conducted in different governorates of Yemen 
have also demonstrated high to medium rates of 
CQ treatment failure, including rates of 61% in the 
Table 4: In vivo Plasmodium falciparum response to chloroquine treatment* in khat- and non-khat-chewing malaria 
patients in Yemen (N = 103)
n (%)
S/RI† RII† RIII† Overall R† TS‡/LTF§ ETF‡
Khat chewers (n = 57) 34 (59.6)¶ 17 (29.8) 6 (10.6) 23 (40.4)¶ 43 (75.4)// 14 (24.6)//
Non-khat chewers (n = 46) 27 (58.7) 10 (21.7) 9 (19.6) 19 (41.3) 33 (71.7) 13 (28.3)
Total 61 (59.2) 27 (26.2) 15 (14.6) 42 (40.8 ) 76 (73.8) 27 (26.2)
S = sensitivity; R = resistance level; TS = treatment success; LTF = late treatment failure; ETF = early treatment failure.
*Total dose of 25 mg/kg over three days.  †According to the 1973 treatment protocol of the World Health Organization.23  ‡According to values 
obtained on day three of treatment and the 1996 treatment protocol of the World Health Organization.24  §According to values obtained on day three 
of treatment and the methods of Osorio et al.25  ¶P = 0.394. //P = 0.823. 
Table 3: Parasitaemia and axillary temperature before (day 
zero) and after (day three) chloroquine treatment* among 
khat- and non-khat-chewing malaria patients in Yemen 
(N = 103)
Mean† parasitaemia 
per µL 
(95% CI) 
Mean axillary 
temperature in °C ± SD
Day 0 Day 3 Day 0 Day 3
Khat 
chewers 
(n = 57)
1,494 
(771–3,837)
3 
(1.7–5.2)
37.5 ± 0.54 36.8 ± 0.11
Non-
khat 
chewers 
(n = 46)
1,861 
(902–2,890)
4
(1.9–7.9)
37.4 ± 0.66 36.8 ± 0.14
P value 0.653 0.563 0.140 0.145
CI = confidence interval; SD = standard deviation.
*Total dose of 25 mg/kg over three days.  †Geometric mean.
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Al-Musaimeer district of Lahj Governorate and 
16.1% in the Hethran and Al-Mafatch districts of 
Taiz Governorate.28,29 In addition, Al-Mekhlafi et al. 
observed a high frequency of P. falciparum CQ 
resistance transporter T76 mutations, suggesting 
considerable CQ resistance among cases of P. 
falciparum-induced malaria in Yemen.30 In the current 
study, parasite densities differed between khat- and 
non-khat-chewing malaria patients, although this 
finding was not significant. Ketema et al. similarly 
observed the mildly antiplasmodial characteristics 
of khat leaves.15 Antimicrobial activity has also been 
reported.31 Several studies have shown that plant 
alkaloids, flavonoids and tannins demonstrate in 
vivo and in vitro antimalarial activity against CQ-
sensitive and -resistant strains of P. falciparum.32,33 
However, further studies are needed to investigate the 
antimalarial activity of khat. The limited reduction in 
parasite densities observed in the current study might 
be attributed to the antiplasmodial activity of certain 
compounds in khat leaves. 
With regards to treatment outcomes, no signifi-
cant differences were found between khat- and non-
khat-chewing malaria patients in the current study. 
However, rates of successful treatment may have 
been overestimated, as certain patients might have 
been classified as cases of LTF instead of TS had they 
been followed-up for a longer period of time (e.g. 
14–28 days). The lack of follow-up and utilisation 
of non-age-matched control and patient groups are 
limitations of the present study. Additionally, the 
difference between cases of S or RI could not be 
distinguished at day two; CQ resistance may therefore 
have been underestimated due to the short follow-up 
period. A further limitation was the use of CQ over 
artemisinin-based combination therapy (ACT). In 
2005, the NMCP in Yemen replaced CQ with ACT 
as the first line of antimalarial therapy. Unfortunately, 
however, this policy was not implemented in practice 
until 2009.16,17 Nevertheless, regardless of current 
antimalarial treatment guidelines, CQ remains the 
second most common antimalarial drug prescribed 
by physicians in public and private health facilities 
in Yemen.16 As such, the results of this study should 
be utilised to educate health workers and medication 
manufacturers in Yemen as to the potential risk of 
CQ co-administration among khat-chewing patients. 
Current anti-malarial drug practices in Yemen should 
be modified accordingly and physicians should 
advise patients not to chew khat whilst undergoing 
CQ treatment. 
Conclusion 
The findings of this study revealed that CQ plasma 
levels were significantly reduced by khat-chewing; 
however, khat-chewing had no significant influence 
on rates of P. falciparum parasite clearance among 
malaria patients. The rate of CQ resistance among 
the patient group was above the acceptable levels 
determined by the WHO, indicating high CQ 
resistance in these areas of Yemen. Based on these 
preliminary findings, patients should be advised not to 
chew khat whilst undergoing CQ treatment.
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